Physician profile
Brandy E Dumas
NPI 1205986395
$1,441.95
in general payments reported to CMS, 2019-2025
18 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $173 · 2023: $436 · 2024: $456 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,269.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $459.28 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $159.73 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $138.05 | 2023-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $110.42 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $93.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $89.26 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $73.18 | 2022-2025 | |
| Abbott Laboratories | $59.21 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Inspire Medical Systems, INC. | $42.87 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.15 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $28.13 | 2025 | Rexulti |
| Hologic Sales and Service, LLC | $26.24 | 2023 | Affirm Prone Biopsy System, Thinprep 2000 Processor, Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $25.60 | 2024 | Trintellix |
| Medtronic, INC. | $23.80 | 2025 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $21.45 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $19.59 | 2023 | Quviviq |
| Amgen INC. | $16.84 | 2025 | Otezla, Repatha |
| Kaleo, INC. | $16.08 | 2023 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Dumas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.